GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Operating Cash Flow per Share

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Operating Cash Flow per Share : $0.13 (TTM As of Mar. 2016)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Operating Cash Flow per Share?

Cancer Prevention Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2016 was $0.06. Cancer Prevention Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2016 was $0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

CPP's 3-Year OCF Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Cancer Prevention Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Operating Cash Flow per Share Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
Operating Cash Flow per Share
- - -0.84

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
Operating Cash Flow per Share Get a 7-Day Free Trial - - - 0.06 0.06

Competitive Comparison of Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Cancer Prevention Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2015 is calculated as

Operating Cash Flow per Share (A: Dec. 2015 )=Cash Flow from Operations (A: Dec. 2015 )/Shares Outstanding (Diluted Average) (A: Dec. 2015 )
=-2.915/3.468
=-0.84

Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2015 is calculated as

Operating Cash Flow per Share (Q: Mar. 2016 )=Cash Flow from Operations (Q: Mar. 2016 )/Shares Outstanding (Diluted Average) (Q: Mar. 2016 )
=0.334/5.495
=0.06

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Prevention Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Headlines